Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

Michael. S. van der Veer,[1] Michel de Weers,[2] Berris van Kessel,[1] Joost M. Bakker,[2] Shulamiet Wittebol,[3] Paul W.H.I. Parren,[2] Henk M. Lokhorst,[4] and Tuna Mutis[1]

[1]Dept. of Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht; [2]Genmab, Utrecht; [3]Dept. of Internal Medicine, Meander Medical Center, Amersfoort, and [4]Dept. of Hematology, University Medical Center Utrecht, Utrecht, Netherlands

Citation: van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PWHI, Lokhorst HM, and Mutis T. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 2011;96(2):284-290. doi:10.3324/haematol.2010.030759



Online Supplementary Figure S1. DARA+LEN does not influence the survival of normal CD38+CD14+ monocytes and CD38+CD16+NK cells in peripheral blood. PBMC from 4 healthy individuals were either left untreated or incubated with DARA (10 μg/mL), LEN (3um) or LEN+DARA. After 72 h the percentage of surviving CD38+CD14+ and CD38+CD16+ cells, which all together comprise over 90% of the CD38+ cells in PBMCs, were determined by FACS analysis as described in the Design and Methods section. To eliminate any hindrance with DARA, cells were labeled with a PE-labeled anti CD38 antibody recognizing a different epitope than DARA. Results represent the mean values. Error bars represent the SEM.



Online Supplementary Figure S2. ADCC effector cells are CD3- cells. PBMC from a healthy donor were MACS separated into a CD3+ and CD3- population. The CD3- population showed lysis after 4 h. As previously described by others this fast acting population consists of NK cells and monocytes.